Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has been included in the new AdvisorShares Psychedelics ETF. The ETF will be traded on the NYSE Arca using the PSIL ticker symbol. The PSIL symbol includes biotechnology, pharmaceutical and life sciences companies that have been identified as leaders in the emerging psychedelics medicine industry. AdvisorShares will be actively managed and focuses investments in companies that derive the majority of their net revenue from psychedelic drugs; companies that allocate the majority of their assets in psychedelic drugs are also included in the ETF. “MINDCURE’s inclusion in the AdvisorShares Psychedelics ETF is further validation of our strategy of integrating digital therapeutics with psychedelic medicine to improve mental health and increase productivity,” said MINDCURE president and CEO Kelsey Ramsden. “MINDCURE is proud to be acknowledged as a leader in this emerging space and our inclusion in the ETF will increase investor awareness to the Company and the benefits of psychedelic treatment methods to improve mental health.”
To view the full press release, visit https://ibn.fm/Q9TFG
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
